Latest Daiichi Sankyo Co. Ltd. Ads (DSNKY) Headlines
Global Biosimilars Market 2014-2018: Patent Expirations and More
M2 - Wed Mar 05, 11:31AM CST
Research and Markets (http://www.researchandmarkets.com/research/jggmhc/global) has announced the addition of the "Global Biosimilars Market 2014-2018" report to their offering. The analysts forecast the Global Biosimilars Market to grow at a CAGR of 27.58 percent over the period 2013-2018. One of the key factors contributing to this market growth is the increasing number of patent expirations. The Global Biosimilars Market has also been witnessing the outsourcing of biosimilar manufacturing. However, the risks related to drug failure could pose a challenge to the growth of this market. Key vendors dominating this space include Biocon Ltd., Hospira Inc., Mylan Inc., Novartis AG, Teva Pharmaceutical Industries Ltd., Intas Pharmaceuticals Ltd., Dr. Reddy's Laboratories Ltd., F. Hoffmann-La Roche Ltd., 3SBio Inc., and Celltrion Inc. Other vendors mentioned in the report are Actavis plc, Amgen Inc., AstraZeneca plc, Baxter International Inc., Biogen Idec Inc., Bioton S.A., Boehringer Ingelheim GmbH, Cipla Ltd., Coherus Biosciences Inc., Daiichi Sankyo Co. Ltd., Emcure Pharmaceuticals Ltd., GE Healthcare Ltd., GeneScience Pharmaceuticals Co. Ltd., GlaxoSmithKline plc, JCR Pharmaceuticals Co. Ltd., iBio Inc., LG Life Sciences Co. Ltd., Merck & Co. Inc., Pfizer Inc., Ranbaxy Laboratories Ltd., Samsung Biologics Co. Ltd., Sanofi S.A., and Wockhardt Ltd. Commenting on the report, an analyst from the team said: The manufacture of biosimilar products requires specialized capabilities, meticulous planning, highly skilled staff, and significant financial investment in equipment, technology, materials, and personnel. Therefore, the complexities and costs involved in the biosimilar development rises along with the dip in their profit margins, hampering the overall success of manufacturing biosimilar products. Thus, many vendors are increasingly turning to CMOs and CROs that have already gained proficiency in the field of manufacturing biosimilar products. The wealth of knowledge, experience, understanding, technology, skills and financial control that CMOs and CROs can provide to manufacturers, make this a solution that many vendors are using at present. These organizations employ well-trained professionals to develop and validate analytical methods, providing pharmaceutical companies with a feasible way of remaining competitive and financially viable. This new trend is expected to have a positive impact on the growth of the market over the next few years. For more information visit http://www.researchandmarkets.com/research/jggmhc/global About Research and Markets Research and Markets is the world's leading source for international market research reports and market data. We provide you with the latest data on international and regional markets, key industries, the top companies, new products and the latest trends.
Concise Analysis of the Future Prospects of Global Personalized Medicine Market
M2 - Tue Mar 04, 5:49AM CST
Research and Markets (http://www.researchandmarkets.com/research/zpctsr/future_prospects) has announced the addition of the "Concise Analysis of the Future Prospects of Global Personalized Medicine Market" report to their offering. Over the years, the Global Personalized Medicine market has been witnessing the emergence of various tools and technologies from the reputed vendors. For instance, AssureRx Health Inc. launched GeneSightRx ADHD in May 2012, a personalized medicine test for the growing number of children and adults diagnosed with ADHD. Moreover, Bristol-Myers Squibb Co. collaborated with MMRF in December 2012 for advanced personalized medicine for multiple Myeloma. Further, Alacris Theranostics GmbH entered into an agreement with GlaxoSmithKline plc in November 2012 to use ModCell system for early stage cancer research. Further, AltheaDx Inc. launched FLT3 Mutation Assay in October 2012. Agendia N.V. launched ColoPrint microarray-based 18-gene expression signature in June 2012 for predicting the risk of distant recurrence for stage II colon cancer patients. The European Medicines Agency approved Zelboraf, manufactured by F. Hoffmann-La Roche Ltd., in December 2011. Key Topics Covered: 1. Executive Summary 2. List of Abbreviations 3. Introduction 4. Market Research Methodology 5. Scope of the Report 6. Market Landscape 7. Geographical Segmentation 8. Key Leading Countries 9. Vendor Landscape 10. Buying Criteria 11. Market Growth Drivers 12. Drivers and their Impact 13. Market Challenges 14. Impact of Drivers and Challenges 15. Market Trends 16. Key Vendor Analysis 17. Other Reports in this Series Companies Mentioned: - Abbott Laboratories - Boehringer Ingelheim GmbH - Bristol-Myers Squibb Co. - Celgene Corp. - Daiichi Sankyo Co. Ltd. - Danaher Corp. - Eli Lilly and Co. - Evotec AG - F. Hoffmann-La Roche Ltd. - GE Healthcare Ltd. - Genelex Corp. - GlaxoSmithKline plc - Hologic Inc. - Johnson & Johnson - Laboratory Corporation of America Holdings - Life Technologies Corp. - Merck KGaA - Mitsubishi Tanabe Pharma Corp. - Myriad Genetics Inc. - Novartis AG - Novartis AG - PerkinElmer Inc. - Pfizer Inc. - Pfizer Inc. - Quest Diagnostics Inc. - Sanofi S.A. - Sanofi S.A. - Siemens Healthcare - Sigma-Aldrich Corp. - Takeda Pharmaceutical Co. Ltd. - Teva Pharmaceutical Industries Ltd. - Thermo Fisher Scientific Inc. - Transgenomic Inc. For more information visit http://www.researchandmarkets.com/research/zp..._prospects
Media Advisory: Public Health Agency of Canada
Marketwire - Fri Feb 21, 2:35PM CST
The Honourable Rona Ambrose, Federal Minister of Health, joined by Canadian Tire and LIFT Philanthropy Partners, will announce an important initiative to encourage children and youth and all Canadians to be more active.
Staphylococcus Aureus Infections - Pipeline Review, H2 2013 Report
M2 - Wed Feb 19, 2:41AM CST
Research and Markets (http://www.researchandmarkets.com/research/jg3jt3/staphylococcus) has announced the addition of the "Staphylococcus Aureus Infections - Pipeline Review, H2 2013" report to their offering. 'Staphylococcus Aureus Infections - Pipeline Review, H2 2013', provides an overview of the indication's therapeutic pipeline. This report provides information on the therapeutic development for Staphylococcus Aureus Infections, complete with latest updates, and special features on late-stage and discontinued projects. It also reviews key players involved in the therapeutic development for Staphylococcus Aureus Infections. Scope - A snapshot of the global therapeutic scenario for Staphylococcus Aureus Infections. - A review of the Staphylococcus Aureus Infections products under development by companies and universities/research institutes based on information derived from company and industry-specific sources. - Coverage of products based on various stages of development ranging from discovery till registration stages. - A feature on pipeline projects on the basis of monotherapy and combined therapeutics. - Coverage of the Staphylococcus Aureus Infections pipeline on the basis of route of administration and molecule type. - Key discontinued pipeline projects. - Latest news and deals relating to the products. Key Topics Covered: Introduction Staphylococcus Aureus Infections Overview Therapeutics Development Clinical Stage Products Early Stage Products Unknown Stage Products Staphylococcus Aureus Infections - Therapeutics Assessment Drug Profiles lysostaphin - Drug Profile WCK-771 - Drug Profile avarofloxacin hydrochloride - Drug Profile PF-06290510 - Drug Profile P-128 - Drug Profile GSK-2392106A - Drug Profile STEBVax - Drug Profile GSK-2392105A - Drug Profile GSK-2392103A - Drug Profile GSK-2392019A - Drug Profile NDV-3 Vaccine - Drug Profile SASPject PT1.2 - Drug Profile GSK-2392102A - Drug Profile Staphylococcus Aureus Vaccine - Drug Profile MEDI-4893 - Drug Profile MORAb-048 - Drug Profile gallium citrate Ga 67 - Drug Profile Staphylococcus Aureus Vaccine - Drug Profile NVC-727 - Drug Profile SEB-HIG - Drug Profile SEB-HuMab - Drug Profile Bactericidal Venom-Based Polypeptides - Drug Profile MGB-BP-3 - Drug Profile Second Generation Oxas - Drug Profile Novarifyn - Drug Profile AQP-182 - Drug Profile niacinamide - Drug Profile Vaccine For Staphylococcus - Drug Profile and many more..... Featured News & Press Releases Appendix List of Tables List of Figures Some of the Companies Mentioned AstraZeneca PLC GlaxoSmithKline plc Genentech, Inc. Daiichi Sankyo Company, Limited Merck & Co., Inc. Exploit Technologies Pte Ltd Imaxio Novartis AG Actelion Ltd Pfizer Inc. Wockhardt Limited NovaBay Pharmaceuticals, Inc. Patrys Limited Galapagos NV Microbio Co., Ltd. Morphotek, Inc. Bharat Biotech International Limited Novabiotics Ltd GlycoVaxyn AG Priaxon AG Aquapharm Biodiscovery Limited Aridis Pharmaceuticals LLC For more information visit http://www.researchandmarkets.com/research/jg...hylococcus About Research and Markets Research and Markets is the world's leading source for international market research reports and market data. We provide you with the latest data on international and regional markets, key industries, the top companies, new products and the latest trends.
Nine-Year-Old YouTube Kid Sells Flappy Bird for 100k on EliteDepot.com
PR Newswire - Tue Feb 11, 7:56AM CST
A nine-year-old kid who goes by the name of CoolGreen1000 is selling his Apple iTouch loaded with the latest updated version of the Flappy Bird application on EliteDepot.com for $100,000. We contacted CoolGreen1000 and asked him about his gaming, his YouTube Channel and his sale of Flappy Bird.
Clostridium Difficile Infections (Clostridium Difficile Associated Disease) - Pipeline Review, H2 2013 Report
M2 - Thu Feb 06, 2:49AM CST
Research and Markets (http://www.researchandmarkets.com/research/c57d4f/clostridium) has announced the addition of the "Clostridium Difficile Infections (Clostridium Difficile Associated Disease) - Pipeline Review, H2 2013" report to their offering. 'Clostridium Difficile Infections (Clostridium Difficile Associated Disease) - Pipeline Review, H2 2013', provides an overview of the indication's therapeutic pipeline. This report provides information on the therapeutic development for Clostridium Difficile Infections (Clostridium Difficile Associated Disease), complete with latest updates, and special features on late-stage and discontinued projects. It also reviews key players involved in the therapeutic development for Clostridium Difficile Infections (Clostridium Difficile Associated Disease). Scope - A snapshot of the global therapeutic scenario for Clostridium Difficile Infections (Clostridium Difficile Associated Disease). - A review of the Clostridium Difficile Infections (Clostridium Difficile Associated Disease) products under development by companies and universities/research institutes based on information derived from company and industry-specific sources. - Coverage of products based on various stages of development ranging from discovery till registration stages. - A feature on pipeline projects on the basis of monotherapy and combined therapeutics. - Coverage of the Clostridium Difficile Infections (Clostridium Difficile Associated Disease) pipeline on the basis of route of administration and molecule type. - Key discontinued pipeline projects. - Latest news and deals relating to the products. Key Topics Covered: Introduction Clostridium Difficile Infections (Clostridium Difficile Associated Disease) Overview Therapeutics Development Late Stage Products Clinical Stage Products Early Stage Products Unknown Stage Products Assessment by Monotherapy Products Assessment by Combination Products Assessment by Target Assessment by Mechanism of Action Assessment by Route of Administration Assessment by Molecule Type Assessment by Therapeutic Class Drug Profiles Featured News & Press Releases Companies Mentioned Sequella, Inc. MedImmune, LLC Daiichi Sankyo Company, Limited AmpliPhi Biosciences Corporation Merck & Co., Inc. Novartis AG Cubist Pharmaceuticals, Inc. The Medicines Company Pfizer Inc. Ranbaxy Laboratories Limited ViroPharma Incorporated Paratek Pharmaceuticals, Inc. Oragenics, Inc. Immuron Limited Summit Corporation plc Novabiotics Ltd ImmunoBiology Ltd. Aquapharm Biodiscovery Limited Microbiotix, Inc. Synthetic Biologics, Inc. AIMM Therapeutics B.V. and many more.... For more information visit http://www.researchandmarkets.com/research/c5...lostridium About Research and Markets Research and Markets is the world's leading source for international market research reports and market data. We provide you with the latest data on international and regional markets, key industries, the top companies, new products and the latest trends.
Concise Analysis of the International Biopharmaceuticals Market
M2 - Fri Jan 31, 6:12AM CST
Research and Markets (http://www.researchandmarkets.com/research/rcw555/biopharmaceuticals) has announced the addition of the "Biopharmaceuticals - A Global Market Overview" report to their offering. The pharmaceutical R&D pipeline and industry have been witnessing greater degree of dependence on biopharmaceuticals. Development of these products is being undertaken by a growing number of players in the pharmaceutical industry, which include the big pharma companies as also generic drug manufacturers, who are also engaged in developing biosimilars. In conjunction with the traditional small biopharmaceutical companies, the new bigger entrants have been focused on continually expanding the global biologics pipeline, implying that the number and proportion of new pharmaceuticals being commercialized would increasingly comprise biopharmaceuticals and not small molecule drugs. As the cost of developing biopharmaceuticals and bringing them to market is generally much higher, offering enhanced profit margins, it comes as no surprise that the global pharmaceutical industry would continue to rely on biopharmaceuticals for profits and innovation, in addition to its very survival. Even though the worldwide economic recession has been slow in recovering, the global pharmaceutical and biopharmaceutical industries have marched ahead, showing profitability and growth. According to estimates, more than 10k therapeutics are currently in the research and development stage, which include chemical substance pharmaceuticals or drugs and biotechnology-derived pharmaceuticals or biopharmaceuticals undergoing over 40k clinical trials. Key Topics Covered: Part A: Global Market Perspective 1. Introduction 2. Key Facts And Figures Of Biopharma Industry And Latest Approvals 3. Key Market Trends 4. Key Global Players 5. Key Business Trends 6. Global Market Overview Part B: Regional Market Perspective Regional Market Overview 1. North America 2. Europe 3. Asia-Pacific 4. South America 5. Rest Of World Part C: Guide To The Industry 1. North America 2. Europe 3. Asia-Pacific 4. Rest Of World Part D: Annexure 1. Research Methodology 2. The Questionnaire 3. Feedback Companies Mentioned: - Abbott Laboratories - Amgen - Astrazeneca - BASF - Bayer - Biocon - Biogen - Boehringer Ingelheim - Bristol-Myers Squibb Company - Daiichi Sankyo Company - Eli Lilly and Company - Genentech - Glaxosmithkline - Hospira - Johnson & Johnson - LG Life Sciences - Novartis - Novo Nordisk - Pfizer - Ranbaxy Laboratories - Roche Holding - Sanofi - Takeda Pharmaceutical Company Limited - Teva Pharmaceutical Industries - UCB For more information visit http://www.researchandmarkets.com/research/rc...aceuticals
Rhabdomyosarcoma - Pipeline Review, H2 2013 Includes Players such as Eli Lilly and Company and Neotropix, Inc.
M2 - Wed Jan 22, 5:32AM CST
Research and Markets (http://www.researchandmarkets.com/research/s85dzx/rhabdomyosarcoma) has announced the addition of the "Rhabdomyosarcoma - Pipeline Review, H2 2013" report to their offering. Global Markets Direct's, 'Rhabdomyosarcoma - Pipeline Review, H2 2013', provides an overview of the indication's therapeutic pipeline. This report provides information on the therapeutic development for Rhabdomyosarcoma, complete with latest updates, and special features on late-stage and discontinued projects. It also reviews key players involved in the therapeutic development for Rhabdomyosarcoma. Rhabdomyosarcoma - Pipeline Review, Half Year is built using data and information sourced from Global Markets Direct's proprietary databases, Company/University websites, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources, put together by Global Markets Direct's team. Scope - A snapshot of the global therapeutic scenario for Rhabdomyosarcoma. - A review of the Rhabdomyosarcoma products under development by companies and universities/research institutes based on information derived from company and industry-specific sources. - Coverage of products based on various stages of development ranging from discovery till registration stages. - A feature on pipeline projects on the basis of monotherapy and combined therapeutics. - Coverage of the Rhabdomyosarcoma pipeline on the basis of route of administration and molecule type. - Key discontinued pipeline projects. - Latest news and deals relating to the products. Companies Mentioned: -Arisaph Pharmaceuticals, Inc. -Celgene Corporation -Daiichi Sankyo Company, Limited -Eli Lilly and Company -Merrimack Pharmaceuticals, Inc. -Neotropix, Inc. -Shionogi & Co., Ltd. -Vaccinex, Inc. For more information visit http://www.researchandmarkets.com/research/s8...myosarcoma About Research and Markets Research and Markets is the world's leading source for international market research reports and market data. We provide you with the latest data on international and regional markets, key industries, the top companies, new products and the latest trends.
Bacterial Conjunctivitis - Pipeline Review, H2 2013 Report Gives a Snapshot of the Global Therapeutic Scenario for Bacterial Conjunctivitis
M2 - Wed Jan 22, 5:17AM CST
Research and Markets (http://www.researchandmarkets.com/research/s6nmg2/bacterial) has announced the addition of the "Bacterial Conjunctivitis - Pipeline Review, H2 2013" report to their offering. Global Markets Direct's, 'Bacterial Conjunctivitis - Pipeline Review, H2 2013', provides an overview of the indication's therapeutic pipeline. This report provides information on the therapeutic development for Bacterial Conjunctivitis, complete with latest updates, and special features on late-stage and discontinued projects. It also reviews key players involved in the therapeutic development for Bacterial Conjunctivitis. Bacterial Conjunctivitis - Pipeline Review, Half Year is built using data and information sourced from Global Markets Direct's proprietary databases, Company/University websites, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources, put together by Global Markets Direct's team. Note*: Certain sections in the report may be removed or altered based on the availability and relevance of data for the indicated disease. Scope - A review of the Bacterial Conjunctivitis products under development by companies and universities/research institutes based on information derived from company and industry-specific sources. - Coverage of products based on various stages of development ranging from discovery till registration stages. - A feature on pipeline projects on the basis of monotherapy and combined therapeutics. - Coverage of the Bacterial Conjunctivitis pipeline on the basis of route of administration and molecule type. - Key discontinued pipeline projects. - Latest news and deals relating to the products. Companies Mentioned: -Cellceutix Corporation -China Grand Wuhan General Pharmaceutical Research Institute -Daiichi Sankyo Company, Limited -EyeGate Pharmaceuticals, Inc. -InSite Vision Incorporated -NovaBay Pharmaceuticals, Inc. -Ocular Therapeutix, Inc. For more information visit http://www.researchandmarkets.com/research/s6nmg2/bacterial About Research and Markets Research and Markets is the world's leading source for international market research reports and market data. We provide you with the latest data on international and regional markets, key industries, the top companies, new products and the latest trends.
Venous Thromboembolism Global Clinical Trials Review, H2 2013 Report
M2 - Fri Jan 17, 9:15AM CST
Research and Markets (http://www.researchandmarkets.com/research/t9vr95/venous) has announced the addition of the "Venous Thromboembolism Global Clinical Trials Review, H2, 2013" report to their offering. Venous Thromboembolism Global Clinical Trials Review, H2, 2013 provides data on the Venous Thromboembolism clinical trial scenario. This report provides elemental information and data relating to the clinical trials on Venous Thromboembolism. It includes an overview of the trial numbers and their recruitment status as per the site of trial conduction across the globe. The databook offers a preliminary coverage of disease clinical trials by their phase, trial status, prominence of the sponsors and also provides briefing pertaining to the number of trials for the key drugs for treating Venous Thromboembolism. Scope - Data on the number of clinical trials conducted in North America, South and Central America, Europe, Middle-East and Africa and Asia-pacific and top five national contributions in each, along with the clinical trial scenario in BRIC nations - Clinical trial (complete and in progress) data by phase, trial status, subjects recruited and sponsor type - Listings of discontinued trials (suspended, withdrawn and terminated) Top Companies Participating in Venous Thromboembolism Therapeutics Clinical Trials - Bayer AG - Sanofi - GlaxoSmithKline plc - C. H. Boehringer Sohn AG & Co. KG - Astellas Pharma Inc. - Daiichi Sankyo Company, Limited - Pfizer Inc. - AstraZeneca PLC - Bristol-Myers Squibb Company - Eisai Co., Ltd. Clinical Trial Overview of Top Institutes / Government - National Heart, Lung, and Blood Institute - Hamilton Health Sciences - Ottawa Hospital Research Institute - Brigham and Women's Hospital - McMaster University - Centre Hospitalier Universitaire de Saint Etienne - Universita di Padova - Mayo Clinic - Universita degli Studi dell'Insubria - The Utrecht Institute for Pharmaceutical Sciences For more information visit http://www.researchandmarkets.com/research/t9vr95/venous
Atrial Fibrillation Global Clinical Trials Review, H2 2013 Report
M2 - Fri Jan 17, 9:04AM CST
Research and Markets (http://www.researchandmarkets.com/research/4ts9mh/atrial) has announced the addition of the "Atrial Fibrillation Global Clinical Trials Review, H2, 2013" report to their offering. Atrial Fibrillation Global Clinical Trials Review, H2, 2013 provides data on the Atrial Fibrillation clinical trial scenario. This report provides elemental information and data relating to the clinical trials on Atrial Fibrillation. It includes an overview of the trial numbers and their recruitment status as per the site of trial conduction across the globe. The databook offers a preliminary coverage of disease clinical trials by their phase, trial status, prominence of the sponsors and also provides briefing pertaining to the number of trials for the key drugs for treating Atrial Fibrillation. Scope - Data on the number of clinical trials conducted in North America, South and Central America, Europe, Middle-East and Africa and Asia-pacific and top five national contributions in each, along with the clinical trial scenario in BRIC nations - Clinical trial (complete and in progress) data by phase, trial status, subjects recruited and sponsor type - Listings of discontinued trials (suspended, withdrawn and terminated) Top Companies Participating in Atrial Fibrillation Therapeutics Clinical Trials - Sanofi - Medtronic, Inc. - AstraZeneca PLC - C. H. Boehringer Sohn AG & Co. KG - Bayer AG - St. Jude Medical, Inc. - Bristol-Myers Squibb Company - Cardiome Pharma Corp - Pfizer Inc. - Daiichi Sankyo Company, Limited Clinical Trial Overview of Top Institutes / Government - National Heart, Lung, and Blood Institute - Texas Cardiac Arrhythmia Research Foundation - Meshalkin Research Institute of Pathology of Circulation - Deutsches Herzzentrum Munchen - Mayo Clinic - Vanderbilt University - Medical University of Vienna - University Medical Center Groningen - University of Pittsburgh - Norwegian University of Science and Technology For more information visit http://www.researchandmarkets.com/research/4ts9mh/atrial
SarlaFlex Inc. Closes $13 Million in NMTC Financing for New U.S. Facility
Marketwire - Fri Jan 17, 8:35AM CST
SarlaFlex Inc. has secured $13 million in New Markets Tax Credit (NMTC) allocation from Los Angeles-based National New Markets Fund, LLC (NNMF) to redevelop a manufacturing facility in rural South Carolina into the company's first U.S. based yarn and thread plant. U.S. Bank serves as the tax credit investor, capitalizing the allocation.
Thromboembolism Global Clinical Trials Review, H2, 2013 - Featuring 10 Leading Pharma Companies and 10 Institutions
M2 - Thu Jan 16, 10:13AM CST
Research and Markets (http://www.researchandmarkets.com/research/kjjw86/thromboembolism) has announced the addition of the "Thromboembolism Global Clinical Trials Review, H2, 2013" report to their offering. Thromboembolism Global Clinical Trials Review, H2, 2013 provides data on the Thromboembolism clinical trial scenario. This report provides elemental information and data relating to the clinical trials on Thromboembolism. It includes an overview of the trial numbers and their recruitment status as per the site of trial conduction across the globe. The databook offers a preliminary coverage of disease clinical trials by their phase, trial status, prominence of the sponsors and also provides briefing pertaining to the number of trials for the key drugs for treating Thromboembolism. Scope - Data on the number of clinical trials conducted in North America, South and Central America, Europe, Middle-East and Africa and Asia-pacific and top five national contributions in each, along with the clinical trial scenario in BRIC nations - Clinical trial (complete and in progress) data by phase, trial status, subjects recruited and sponsor type - Listings of discontinued trials (suspended, withdrawn and terminated) Top Companies Participating in Thromboembolism Therapeutics Clinical Trials - Bayer AG - Sanofi - C. H. Boehringer Sohn AG & Co. KG - GlaxoSmithKline plc - Astellas Pharma Inc. - Pfizer Inc. - Daiichi Sankyo Company, Limited - AstraZeneca PLC - Bristol-Myers Squibb Company - The LEO Foundation Clinical Trial Overview of Top Institutes / Government - National Heart, Lung, and Blood Institute - Ottawa Hospital Research Institute - Hamilton Health Sciences - Beijing Chao Yang Hospital - University of Zurich - Brigham and Women's Hospital - Capital District Health Authority, Canada - McMaster University - Centre Hospitalier Universitaire de Saint Etienne - Universita di Padova For more information visit http://www.researchandmarkets.com/research/kj...boembolism
Pieris Achieves Fourth Milestone Payment in Daiichi Sankyo Collaboration to Develop Anticalin(R) Therapeutics
Business Wire - Mon Jan 13, 1:59AM CST
Pieris AG has achieved the third milestone for its lead Anticalin(R) program with Daiichi Sankyo Company Limited (hereinafter Daiichi Sankyo; headquartered in Chuo Ward, Tokyo, TSE 4568), triggering an undisclosed payment, the company announced today. This milestone marks in total the fourth milestone achieved for the parties' two R&D collaborative projects. Specifically, the milestone achieved was the progression of an Anticalin drug candidate through a non-GLP toxicity study in non-human primates. In 2013, Pieris transferred the program to Daiichi Sankyo, which successfully carried out this study.
CounterPath to Present at Needham Growth Conference
Marketwire Canada - Thu Jan 09, 6:57PM CST
CounterPath Corporation (NASDAQ:CPAH)(TSX:CCV), an award-winning provider of desktop and mobile VoIP software products and solutions, announces that Donovan Jones, President and Chief Executive Officer, will present at the 16th Annual Needham Growth Conference. Mr. Jones will outline CounterPath's VoIP software and services, its customer relationships, its IP portfolio and the sector outlook.
Daiichi Sankyo Submits SAVAYSA(TM) (edoxaban) Tablets New Drug Application to the U.S. FDA for Once-Daily Use for Stroke Risk Reduction in Atrial Fibrillation and for the Treatment and Prevention of Recurrence of Venous Thromboembolism
PR Newswire Europe - Wed Jan 08, 12:09PM CST
-- Submission based on the two largest comparative phase 3 clinical trials of a novel oral anticoagulant in patients with non-valvular atrial fibrillation or symptomatic venous thromboembolism
Daiichi Sankyo, Virtici and Celdara Medical Announce Collaboration to Identify and Progress High Potential Therapeutics
PR Newswire - Wed Jan 08, 7:30AM CST
Daiichi Sankyo, Co., Ltd., Virtici, LLC and Celdara Medical, LLC announced today that they have entered into a collaboration to jointly investigate novel therapeutic candidates and thereby further strengthen the Daiichi Sankyo developmental pipeline across multiple therapeutic areas.
EPIRUS and Ranbaxy Announce Signing of BOW015 Licensing Partnership For Broad Range of Territories
Business Wire - Wed Jan 08, 4:59AM CST
EPIRUS Switzerland GmbH, a wholly-owned subsidiary of Boston-based EPIRUS Biopharmaceuticals, Inc. ("EPIRUS"), and Ranbaxy Laboratories Limited ("RANBAXY") a division of Daiichi Sankyo Company, Tokyo, today announced the signing of a licensing agreement for BOW015, a biosimilar infliximab, for the broad range of territories including India, selected South East Asian markets, North Africa and several other markets.
Global Biosimilars Market 2014-2018: Patent Expirations and More
M2 - Wed Mar 05, 11:31AM CST
Research and Markets (http://www.researchandmarkets.com/research/jggmhc/global) has announced the addition of the "Global Biosimilars Market 2014-2018" report to their offering. The analysts forecast the Global Biosimilars Market to grow at a CAGR of 27.58 percent over the period 2013-2018. One of the key factors contributing to this market growth is the increasing number of patent expirations. The Global Biosimilars Market has also been witnessing the outsourcing of biosimilar manufacturing. However, the risks related to drug failure could pose a challenge to the growth of this market. Key vendors dominating this space include Biocon Ltd., Hospira Inc., Mylan Inc., Novartis AG, Teva Pharmaceutical Industries Ltd., Intas Pharmaceuticals Ltd., Dr. Reddy's Laboratories Ltd., F. Hoffmann-La Roche Ltd., 3SBio Inc., and Celltrion Inc. Other vendors mentioned in the report are Actavis plc, Amgen Inc., AstraZeneca plc, Baxter International Inc., Biogen Idec Inc., Bioton S.A., Boehringer Ingelheim GmbH, Cipla Ltd., Coherus Biosciences Inc., Daiichi Sankyo Co. Ltd., Emcure Pharmaceuticals Ltd., GE Healthcare Ltd., GeneScience Pharmaceuticals Co. Ltd., GlaxoSmithKline plc, JCR Pharmaceuticals Co. Ltd., iBio Inc., LG Life Sciences Co. Ltd., Merck & Co. Inc., Pfizer Inc., Ranbaxy Laboratories Ltd., Samsung Biologics Co. Ltd., Sanofi S.A., and Wockhardt Ltd. Commenting on the report, an analyst from the team said: The manufacture of biosimilar products requires specialized capabilities, meticulous planning, highly skilled staff, and significant financial investment in equipment, technology, materials, and personnel. Therefore, the complexities and costs involved in the biosimilar development rises along with the dip in their profit margins, hampering the overall success of manufacturing biosimilar products. Thus, many vendors are increasingly turning to CMOs and CROs that have already gained proficiency in the field of manufacturing biosimilar products. The wealth of knowledge, experience, understanding, technology, skills and financial control that CMOs and CROs can provide to manufacturers, make this a solution that many vendors are using at present. These organizations employ well-trained professionals to develop and validate analytical methods, providing pharmaceutical companies with a feasible way of remaining competitive and financially viable. This new trend is expected to have a positive impact on the growth of the market over the next few years. For more information visit http://www.researchandmarkets.com/research/jggmhc/global About Research and Markets Research and Markets is the world's leading source for international market research reports and market data. We provide you with the latest data on international and regional markets, key industries, the top companies, new products and the latest trends.
Concise Analysis of the Future Prospects of Global Personalized Medicine Market
M2 - Tue Mar 04, 5:49AM CST
Research and Markets (http://www.researchandmarkets.com/research/zpctsr/future_prospects) has announced the addition of the "Concise Analysis of the Future Prospects of Global Personalized Medicine Market" report to their offering. Over the years, the Global Personalized Medicine market has been witnessing the emergence of various tools and technologies from the reputed vendors. For instance, AssureRx Health Inc. launched GeneSightRx ADHD in May 2012, a personalized medicine test for the growing number of children and adults diagnosed with ADHD. Moreover, Bristol-Myers Squibb Co. collaborated with MMRF in December 2012 for advanced personalized medicine for multiple Myeloma. Further, Alacris Theranostics GmbH entered into an agreement with GlaxoSmithKline plc in November 2012 to use ModCell system for early stage cancer research. Further, AltheaDx Inc. launched FLT3 Mutation Assay in October 2012. Agendia N.V. launched ColoPrint microarray-based 18-gene expression signature in June 2012 for predicting the risk of distant recurrence for stage II colon cancer patients. The European Medicines Agency approved Zelboraf, manufactured by F. Hoffmann-La Roche Ltd., in December 2011. Key Topics Covered: 1. Executive Summary 2. List of Abbreviations 3. Introduction 4. Market Research Methodology 5. Scope of the Report 6. Market Landscape 7. Geographical Segmentation 8. Key Leading Countries 9. Vendor Landscape 10. Buying Criteria 11. Market Growth Drivers 12. Drivers and their Impact 13. Market Challenges 14. Impact of Drivers and Challenges 15. Market Trends 16. Key Vendor Analysis 17. Other Reports in this Series Companies Mentioned: - Abbott Laboratories - Boehringer Ingelheim GmbH - Bristol-Myers Squibb Co. - Celgene Corp. - Daiichi Sankyo Co. Ltd. - Danaher Corp. - Eli Lilly and Co. - Evotec AG - F. Hoffmann-La Roche Ltd. - GE Healthcare Ltd. - Genelex Corp. - GlaxoSmithKline plc - Hologic Inc. - Johnson & Johnson - Laboratory Corporation of America Holdings - Life Technologies Corp. - Merck KGaA - Mitsubishi Tanabe Pharma Corp. - Myriad Genetics Inc. - Novartis AG - Novartis AG - PerkinElmer Inc. - Pfizer Inc. - Pfizer Inc. - Quest Diagnostics Inc. - Sanofi S.A. - Sanofi S.A. - Siemens Healthcare - Sigma-Aldrich Corp. - Takeda Pharmaceutical Co. Ltd. - Teva Pharmaceutical Industries Ltd. - Thermo Fisher Scientific Inc. - Transgenomic Inc. For more information visit http://www.researchandmarkets.com/research/zp..._prospects
Media Advisory: Public Health Agency of Canada
Marketwire - Fri Feb 21, 2:35PM CST
The Honourable Rona Ambrose, Federal Minister of Health, joined by Canadian Tire and LIFT Philanthropy Partners, will announce an important initiative to encourage children and youth and all Canadians to be more active.
Staphylococcus Aureus Infections - Pipeline Review, H2 2013 Report
M2 - Wed Feb 19, 2:41AM CST
Research and Markets (http://www.researchandmarkets.com/research/jg3jt3/staphylococcus) has announced the addition of the "Staphylococcus Aureus Infections - Pipeline Review, H2 2013" report to their offering. 'Staphylococcus Aureus Infections - Pipeline Review, H2 2013', provides an overview of the indication's therapeutic pipeline. This report provides information on the therapeutic development for Staphylococcus Aureus Infections, complete with latest updates, and special features on late-stage and discontinued projects. It also reviews key players involved in the therapeutic development for Staphylococcus Aureus Infections. Scope - A snapshot of the global therapeutic scenario for Staphylococcus Aureus Infections. - A review of the Staphylococcus Aureus Infections products under development by companies and universities/research institutes based on information derived from company and industry-specific sources. - Coverage of products based on various stages of development ranging from discovery till registration stages. - A feature on pipeline projects on the basis of monotherapy and combined therapeutics. - Coverage of the Staphylococcus Aureus Infections pipeline on the basis of route of administration and molecule type. - Key discontinued pipeline projects. - Latest news and deals relating to the products. Key Topics Covered: Introduction Staphylococcus Aureus Infections Overview Therapeutics Development Clinical Stage Products Early Stage Products Unknown Stage Products Staphylococcus Aureus Infections - Therapeutics Assessment Drug Profiles lysostaphin - Drug Profile WCK-771 - Drug Profile avarofloxacin hydrochloride - Drug Profile PF-06290510 - Drug Profile P-128 - Drug Profile GSK-2392106A - Drug Profile STEBVax - Drug Profile GSK-2392105A - Drug Profile GSK-2392103A - Drug Profile GSK-2392019A - Drug Profile NDV-3 Vaccine - Drug Profile SASPject PT1.2 - Drug Profile GSK-2392102A - Drug Profile Staphylococcus Aureus Vaccine - Drug Profile MEDI-4893 - Drug Profile MORAb-048 - Drug Profile gallium citrate Ga 67 - Drug Profile Staphylococcus Aureus Vaccine - Drug Profile NVC-727 - Drug Profile SEB-HIG - Drug Profile SEB-HuMab - Drug Profile Bactericidal Venom-Based Polypeptides - Drug Profile MGB-BP-3 - Drug Profile Second Generation Oxas - Drug Profile Novarifyn - Drug Profile AQP-182 - Drug Profile niacinamide - Drug Profile Vaccine For Staphylococcus - Drug Profile and many more..... Featured News & Press Releases Appendix List of Tables List of Figures Some of the Companies Mentioned AstraZeneca PLC GlaxoSmithKline plc Genentech, Inc. Daiichi Sankyo Company, Limited Merck & Co., Inc. Exploit Technologies Pte Ltd Imaxio Novartis AG Actelion Ltd Pfizer Inc. Wockhardt Limited NovaBay Pharmaceuticals, Inc. Patrys Limited Galapagos NV Microbio Co., Ltd. Morphotek, Inc. Bharat Biotech International Limited Novabiotics Ltd GlycoVaxyn AG Priaxon AG Aquapharm Biodiscovery Limited Aridis Pharmaceuticals LLC For more information visit http://www.researchandmarkets.com/research/jg...hylococcus About Research and Markets Research and Markets is the world's leading source for international market research reports and market data. We provide you with the latest data on international and regional markets, key industries, the top companies, new products and the latest trends.
Nine-Year-Old YouTube Kid Sells Flappy Bird for 100k on EliteDepot.com
PR Newswire - Tue Feb 11, 7:56AM CST
A nine-year-old kid who goes by the name of CoolGreen1000 is selling his Apple iTouch loaded with the latest updated version of the Flappy Bird application on EliteDepot.com for $100,000. We contacted CoolGreen1000 and asked him about his gaming, his YouTube Channel and his sale of Flappy Bird.
Clostridium Difficile Infections (Clostridium Difficile Associated Disease) - Pipeline Review, H2 2013 Report
M2 - Thu Feb 06, 2:49AM CST
Research and Markets (http://www.researchandmarkets.com/research/c57d4f/clostridium) has announced the addition of the "Clostridium Difficile Infections (Clostridium Difficile Associated Disease) - Pipeline Review, H2 2013" report to their offering. 'Clostridium Difficile Infections (Clostridium Difficile Associated Disease) - Pipeline Review, H2 2013', provides an overview of the indication's therapeutic pipeline. This report provides information on the therapeutic development for Clostridium Difficile Infections (Clostridium Difficile Associated Disease), complete with latest updates, and special features on late-stage and discontinued projects. It also reviews key players involved in the therapeutic development for Clostridium Difficile Infections (Clostridium Difficile Associated Disease). Scope - A snapshot of the global therapeutic scenario for Clostridium Difficile Infections (Clostridium Difficile Associated Disease). - A review of the Clostridium Difficile Infections (Clostridium Difficile Associated Disease) products under development by companies and universities/research institutes based on information derived from company and industry-specific sources. - Coverage of products based on various stages of development ranging from discovery till registration stages. - A feature on pipeline projects on the basis of monotherapy and combined therapeutics. - Coverage of the Clostridium Difficile Infections (Clostridium Difficile Associated Disease) pipeline on the basis of route of administration and molecule type. - Key discontinued pipeline projects. - Latest news and deals relating to the products. Key Topics Covered: Introduction Clostridium Difficile Infections (Clostridium Difficile Associated Disease) Overview Therapeutics Development Late Stage Products Clinical Stage Products Early Stage Products Unknown Stage Products Assessment by Monotherapy Products Assessment by Combination Products Assessment by Target Assessment by Mechanism of Action Assessment by Route of Administration Assessment by Molecule Type Assessment by Therapeutic Class Drug Profiles Featured News & Press Releases Companies Mentioned Sequella, Inc. MedImmune, LLC Daiichi Sankyo Company, Limited AmpliPhi Biosciences Corporation Merck & Co., Inc. Novartis AG Cubist Pharmaceuticals, Inc. The Medicines Company Pfizer Inc. Ranbaxy Laboratories Limited ViroPharma Incorporated Paratek Pharmaceuticals, Inc. Oragenics, Inc. Immuron Limited Summit Corporation plc Novabiotics Ltd ImmunoBiology Ltd. Aquapharm Biodiscovery Limited Microbiotix, Inc. Synthetic Biologics, Inc. AIMM Therapeutics B.V. and many more.... For more information visit http://www.researchandmarkets.com/research/c5...lostridium About Research and Markets Research and Markets is the world's leading source for international market research reports and market data. We provide you with the latest data on international and regional markets, key industries, the top companies, new products and the latest trends.
Concise Analysis of the International Biopharmaceuticals Market
M2 - Fri Jan 31, 6:12AM CST
Research and Markets (http://www.researchandmarkets.com/research/rcw555/biopharmaceuticals) has announced the addition of the "Biopharmaceuticals - A Global Market Overview" report to their offering. The pharmaceutical R&D pipeline and industry have been witnessing greater degree of dependence on biopharmaceuticals. Development of these products is being undertaken by a growing number of players in the pharmaceutical industry, which include the big pharma companies as also generic drug manufacturers, who are also engaged in developing biosimilars. In conjunction with the traditional small biopharmaceutical companies, the new bigger entrants have been focused on continually expanding the global biologics pipeline, implying that the number and proportion of new pharmaceuticals being commercialized would increasingly comprise biopharmaceuticals and not small molecule drugs. As the cost of developing biopharmaceuticals and bringing them to market is generally much higher, offering enhanced profit margins, it comes as no surprise that the global pharmaceutical industry would continue to rely on biopharmaceuticals for profits and innovation, in addition to its very survival. Even though the worldwide economic recession has been slow in recovering, the global pharmaceutical and biopharmaceutical industries have marched ahead, showing profitability and growth. According to estimates, more than 10k therapeutics are currently in the research and development stage, which include chemical substance pharmaceuticals or drugs and biotechnology-derived pharmaceuticals or biopharmaceuticals undergoing over 40k clinical trials. Key Topics Covered: Part A: Global Market Perspective 1. Introduction 2. Key Facts And Figures Of Biopharma Industry And Latest Approvals 3. Key Market Trends 4. Key Global Players 5. Key Business Trends 6. Global Market Overview Part B: Regional Market Perspective Regional Market Overview 1. North America 2. Europe 3. Asia-Pacific 4. South America 5. Rest Of World Part C: Guide To The Industry 1. North America 2. Europe 3. Asia-Pacific 4. Rest Of World Part D: Annexure 1. Research Methodology 2. The Questionnaire 3. Feedback Companies Mentioned: - Abbott Laboratories - Amgen - Astrazeneca - BASF - Bayer - Biocon - Biogen - Boehringer Ingelheim - Bristol-Myers Squibb Company - Daiichi Sankyo Company - Eli Lilly and Company - Genentech - Glaxosmithkline - Hospira - Johnson & Johnson - LG Life Sciences - Novartis - Novo Nordisk - Pfizer - Ranbaxy Laboratories - Roche Holding - Sanofi - Takeda Pharmaceutical Company Limited - Teva Pharmaceutical Industries - UCB For more information visit http://www.researchandmarkets.com/research/rc...aceuticals
Rhabdomyosarcoma - Pipeline Review, H2 2013 Includes Players such as Eli Lilly and Company and Neotropix, Inc.
M2 - Wed Jan 22, 5:32AM CST
Research and Markets (http://www.researchandmarkets.com/research/s85dzx/rhabdomyosarcoma) has announced the addition of the "Rhabdomyosarcoma - Pipeline Review, H2 2013" report to their offering. Global Markets Direct's, 'Rhabdomyosarcoma - Pipeline Review, H2 2013', provides an overview of the indication's therapeutic pipeline. This report provides information on the therapeutic development for Rhabdomyosarcoma, complete with latest updates, and special features on late-stage and discontinued projects. It also reviews key players involved in the therapeutic development for Rhabdomyosarcoma. Rhabdomyosarcoma - Pipeline Review, Half Year is built using data and information sourced from Global Markets Direct's proprietary databases, Company/University websites, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources, put together by Global Markets Direct's team. Scope - A snapshot of the global therapeutic scenario for Rhabdomyosarcoma. - A review of the Rhabdomyosarcoma products under development by companies and universities/research institutes based on information derived from company and industry-specific sources. - Coverage of products based on various stages of development ranging from discovery till registration stages. - A feature on pipeline projects on the basis of monotherapy and combined therapeutics. - Coverage of the Rhabdomyosarcoma pipeline on the basis of route of administration and molecule type. - Key discontinued pipeline projects. - Latest news and deals relating to the products. Companies Mentioned: -Arisaph Pharmaceuticals, Inc. -Celgene Corporation -Daiichi Sankyo Company, Limited -Eli Lilly and Company -Merrimack Pharmaceuticals, Inc. -Neotropix, Inc. -Shionogi & Co., Ltd. -Vaccinex, Inc. For more information visit http://www.researchandmarkets.com/research/s8...myosarcoma About Research and Markets Research and Markets is the world's leading source for international market research reports and market data. We provide you with the latest data on international and regional markets, key industries, the top companies, new products and the latest trends.
Bacterial Conjunctivitis - Pipeline Review, H2 2013 Report Gives a Snapshot of the Global Therapeutic Scenario for Bacterial Conjunctivitis
M2 - Wed Jan 22, 5:17AM CST
Research and Markets (http://www.researchandmarkets.com/research/s6nmg2/bacterial) has announced the addition of the "Bacterial Conjunctivitis - Pipeline Review, H2 2013" report to their offering. Global Markets Direct's, 'Bacterial Conjunctivitis - Pipeline Review, H2 2013', provides an overview of the indication's therapeutic pipeline. This report provides information on the therapeutic development for Bacterial Conjunctivitis, complete with latest updates, and special features on late-stage and discontinued projects. It also reviews key players involved in the therapeutic development for Bacterial Conjunctivitis. Bacterial Conjunctivitis - Pipeline Review, Half Year is built using data and information sourced from Global Markets Direct's proprietary databases, Company/University websites, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources, put together by Global Markets Direct's team. Note*: Certain sections in the report may be removed or altered based on the availability and relevance of data for the indicated disease. Scope - A review of the Bacterial Conjunctivitis products under development by companies and universities/research institutes based on information derived from company and industry-specific sources. - Coverage of products based on various stages of development ranging from discovery till registration stages. - A feature on pipeline projects on the basis of monotherapy and combined therapeutics. - Coverage of the Bacterial Conjunctivitis pipeline on the basis of route of administration and molecule type. - Key discontinued pipeline projects. - Latest news and deals relating to the products. Companies Mentioned: -Cellceutix Corporation -China Grand Wuhan General Pharmaceutical Research Institute -Daiichi Sankyo Company, Limited -EyeGate Pharmaceuticals, Inc. -InSite Vision Incorporated -NovaBay Pharmaceuticals, Inc. -Ocular Therapeutix, Inc. For more information visit http://www.researchandmarkets.com/research/s6nmg2/bacterial About Research and Markets Research and Markets is the world's leading source for international market research reports and market data. We provide you with the latest data on international and regional markets, key industries, the top companies, new products and the latest trends.
Venous Thromboembolism Global Clinical Trials Review, H2 2013 Report
M2 - Fri Jan 17, 9:15AM CST
Research and Markets (http://www.researchandmarkets.com/research/t9vr95/venous) has announced the addition of the "Venous Thromboembolism Global Clinical Trials Review, H2, 2013" report to their offering. Venous Thromboembolism Global Clinical Trials Review, H2, 2013 provides data on the Venous Thromboembolism clinical trial scenario. This report provides elemental information and data relating to the clinical trials on Venous Thromboembolism. It includes an overview of the trial numbers and their recruitment status as per the site of trial conduction across the globe. The databook offers a preliminary coverage of disease clinical trials by their phase, trial status, prominence of the sponsors and also provides briefing pertaining to the number of trials for the key drugs for treating Venous Thromboembolism. Scope - Data on the number of clinical trials conducted in North America, South and Central America, Europe, Middle-East and Africa and Asia-pacific and top five national contributions in each, along with the clinical trial scenario in BRIC nations - Clinical trial (complete and in progress) data by phase, trial status, subjects recruited and sponsor type - Listings of discontinued trials (suspended, withdrawn and terminated) Top Companies Participating in Venous Thromboembolism Therapeutics Clinical Trials - Bayer AG - Sanofi - GlaxoSmithKline plc - C. H. Boehringer Sohn AG & Co. KG - Astellas Pharma Inc. - Daiichi Sankyo Company, Limited - Pfizer Inc. - AstraZeneca PLC - Bristol-Myers Squibb Company - Eisai Co., Ltd. Clinical Trial Overview of Top Institutes / Government - National Heart, Lung, and Blood Institute - Hamilton Health Sciences - Ottawa Hospital Research Institute - Brigham and Women's Hospital - McMaster University - Centre Hospitalier Universitaire de Saint Etienne - Universita di Padova - Mayo Clinic - Universita degli Studi dell'Insubria - The Utrecht Institute for Pharmaceutical Sciences For more information visit http://www.researchandmarkets.com/research/t9vr95/venous
Atrial Fibrillation Global Clinical Trials Review, H2 2013 Report
M2 - Fri Jan 17, 9:04AM CST
Research and Markets (http://www.researchandmarkets.com/research/4ts9mh/atrial) has announced the addition of the "Atrial Fibrillation Global Clinical Trials Review, H2, 2013" report to their offering. Atrial Fibrillation Global Clinical Trials Review, H2, 2013 provides data on the Atrial Fibrillation clinical trial scenario. This report provides elemental information and data relating to the clinical trials on Atrial Fibrillation. It includes an overview of the trial numbers and their recruitment status as per the site of trial conduction across the globe. The databook offers a preliminary coverage of disease clinical trials by their phase, trial status, prominence of the sponsors and also provides briefing pertaining to the number of trials for the key drugs for treating Atrial Fibrillation. Scope - Data on the number of clinical trials conducted in North America, South and Central America, Europe, Middle-East and Africa and Asia-pacific and top five national contributions in each, along with the clinical trial scenario in BRIC nations - Clinical trial (complete and in progress) data by phase, trial status, subjects recruited and sponsor type - Listings of discontinued trials (suspended, withdrawn and terminated) Top Companies Participating in Atrial Fibrillation Therapeutics Clinical Trials - Sanofi - Medtronic, Inc. - AstraZeneca PLC - C. H. Boehringer Sohn AG & Co. KG - Bayer AG - St. Jude Medical, Inc. - Bristol-Myers Squibb Company - Cardiome Pharma Corp - Pfizer Inc. - Daiichi Sankyo Company, Limited Clinical Trial Overview of Top Institutes / Government - National Heart, Lung, and Blood Institute - Texas Cardiac Arrhythmia Research Foundation - Meshalkin Research Institute of Pathology of Circulation - Deutsches Herzzentrum Munchen - Mayo Clinic - Vanderbilt University - Medical University of Vienna - University Medical Center Groningen - University of Pittsburgh - Norwegian University of Science and Technology For more information visit http://www.researchandmarkets.com/research/4ts9mh/atrial
SarlaFlex Inc. Closes $13 Million in NMTC Financing for New U.S. Facility
Marketwire - Fri Jan 17, 8:35AM CST
SarlaFlex Inc. has secured $13 million in New Markets Tax Credit (NMTC) allocation from Los Angeles-based National New Markets Fund, LLC (NNMF) to redevelop a manufacturing facility in rural South Carolina into the company's first U.S. based yarn and thread plant. U.S. Bank serves as the tax credit investor, capitalizing the allocation.
Thromboembolism Global Clinical Trials Review, H2, 2013 - Featuring 10 Leading Pharma Companies and 10 Institutions
M2 - Thu Jan 16, 10:13AM CST
Research and Markets (http://www.researchandmarkets.com/research/kjjw86/thromboembolism) has announced the addition of the "Thromboembolism Global Clinical Trials Review, H2, 2013" report to their offering. Thromboembolism Global Clinical Trials Review, H2, 2013 provides data on the Thromboembolism clinical trial scenario. This report provides elemental information and data relating to the clinical trials on Thromboembolism. It includes an overview of the trial numbers and their recruitment status as per the site of trial conduction across the globe. The databook offers a preliminary coverage of disease clinical trials by their phase, trial status, prominence of the sponsors and also provides briefing pertaining to the number of trials for the key drugs for treating Thromboembolism. Scope - Data on the number of clinical trials conducted in North America, South and Central America, Europe, Middle-East and Africa and Asia-pacific and top five national contributions in each, along with the clinical trial scenario in BRIC nations - Clinical trial (complete and in progress) data by phase, trial status, subjects recruited and sponsor type - Listings of discontinued trials (suspended, withdrawn and terminated) Top Companies Participating in Thromboembolism Therapeutics Clinical Trials - Bayer AG - Sanofi - C. H. Boehringer Sohn AG & Co. KG - GlaxoSmithKline plc - Astellas Pharma Inc. - Pfizer Inc. - Daiichi Sankyo Company, Limited - AstraZeneca PLC - Bristol-Myers Squibb Company - The LEO Foundation Clinical Trial Overview of Top Institutes / Government - National Heart, Lung, and Blood Institute - Ottawa Hospital Research Institute - Hamilton Health Sciences - Beijing Chao Yang Hospital - University of Zurich - Brigham and Women's Hospital - Capital District Health Authority, Canada - McMaster University - Centre Hospitalier Universitaire de Saint Etienne - Universita di Padova For more information visit http://www.researchandmarkets.com/research/kj...boembolism
Pieris Achieves Fourth Milestone Payment in Daiichi Sankyo Collaboration to Develop Anticalin(R) Therapeutics
Business Wire - Mon Jan 13, 1:59AM CST
Pieris AG has achieved the third milestone for its lead Anticalin(R) program with Daiichi Sankyo Company Limited (hereinafter Daiichi Sankyo; headquartered in Chuo Ward, Tokyo, TSE 4568), triggering an undisclosed payment, the company announced today. This milestone marks in total the fourth milestone achieved for the parties' two R&D collaborative projects. Specifically, the milestone achieved was the progression of an Anticalin drug candidate through a non-GLP toxicity study in non-human primates. In 2013, Pieris transferred the program to Daiichi Sankyo, which successfully carried out this study.
CounterPath to Present at Needham Growth Conference
Marketwire Canada - Thu Jan 09, 6:57PM CST
CounterPath Corporation (NASDAQ:CPAH)(TSX:CCV), an award-winning provider of desktop and mobile VoIP software products and solutions, announces that Donovan Jones, President and Chief Executive Officer, will present at the 16th Annual Needham Growth Conference. Mr. Jones will outline CounterPath's VoIP software and services, its customer relationships, its IP portfolio and the sector outlook.
Daiichi Sankyo Submits SAVAYSA(TM) (edoxaban) Tablets New Drug Application to the U.S. FDA for Once-Daily Use for Stroke Risk Reduction in Atrial Fibrillation and for the Treatment and Prevention of Recurrence of Venous Thromboembolism
PR Newswire Europe - Wed Jan 08, 12:09PM CST
-- Submission based on the two largest comparative phase 3 clinical trials of a novel oral anticoagulant in patients with non-valvular atrial fibrillation or symptomatic venous thromboembolism
Daiichi Sankyo, Virtici and Celdara Medical Announce Collaboration to Identify and Progress High Potential Therapeutics
PR Newswire - Wed Jan 08, 7:30AM CST
Daiichi Sankyo, Co., Ltd., Virtici, LLC and Celdara Medical, LLC announced today that they have entered into a collaboration to jointly investigate novel therapeutic candidates and thereby further strengthen the Daiichi Sankyo developmental pipeline across multiple therapeutic areas.
EPIRUS and Ranbaxy Announce Signing of BOW015 Licensing Partnership For Broad Range of Territories
Business Wire - Wed Jan 08, 4:59AM CST
EPIRUS Switzerland GmbH, a wholly-owned subsidiary of Boston-based EPIRUS Biopharmaceuticals, Inc. ("EPIRUS"), and Ranbaxy Laboratories Limited ("RANBAXY") a division of Daiichi Sankyo Company, Tokyo, today announced the signing of a licensing agreement for BOW015, a biosimilar infliximab, for the broad range of territories including India, selected South East Asian markets, North Africa and several other markets.
